Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.
| Ipamorelin | LL-37 (Cathelicidin) | |
|---|---|---|
| Category | Peptides | Peptides |
| Standard Dose | Research indicates 200-300 mcg administered 1-3 times daily via subcutaneous injection. | Research indicates 50-100 mcg daily via subcutaneous injection for immune support. |
| Timing | Best administered at bedtime for synergy with natural GH peak. Also effective upon waking and post-workout. Always on empty stomach. | Morning administration preferred for immune support. Topical application directly to wound sites. |
| Cycle Duration | 12-24 week cycles with 4-8 week breaks. | 4-8 week cycles. Short-term use preferred due to limited long-term safety data. |
| Evidence Level | moderate_human | animal_plus_anecdotal |
Ipamorelin is a pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) that acts as the first selective growth hormone secretagogue receptor (GHS-R1a/ghrelin receptor) agonist. Unlike other GHRPs, it selectively stimulates GH release without significantly affecting ACTH, cortisol, prolactin, or aldosterone — even at doses 200-fold above the ED50 for GH release. This selectivity profile is comparable to GHRH itself but operates through the distinct ghrelin receptor on pituitary somatotrophs.
Research indicates 200-300 mcg administered 1-3 times daily via subcutaneous injection.
Best administered at bedtime for synergy with natural GH peak. Also effective upon waking and post-workout. Always on empty stomach.
12-24 week cycles with 4-8 week breaks.
LL-37 is a 37-residue amphipathic helical antimicrobial peptide, the only human cathelicidin, that kills bacteria by forming tetrameric channels that perforate cytoplasmic membranes. Beyond direct antimicrobial activity, it modulates innate immunity through formyl-peptide receptor 2 (FPR2), induces chemotaxis of neutrophils and monocytes, upregulates CXCR4 and IL-8, and neutralizes bacterial endotoxins (LPS). It also promotes wound healing through keratinocyte migration and angiogenesis.
Research indicates 50-100 mcg daily via subcutaneous injection for immune support.
Morning administration preferred for immune support. Topical application directly to wound sites.
4-8 week cycles. Short-term use preferred due to limited long-term safety data.
Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.
Get Your Free Protocol →or take the assessment →